Facebook
Twitter
LinkedIn
ForwardON-DEMAND: ANTINEOPLASTIC THERAPY AND IMMUNOTHERAPY COURSE
The On-Demand UPMC Antineoplastic Therapy and Immunotherapy Course contains the elements of the live four-day activity but allows the participant to access the learning on their own schedule. Those enrolled in the course are required to complete all video modules containing lectures from the four-day course. Once all videos have been viewed, complete the evaluation to receive 22.75 continuing education credits. Notify your manager to contact course director to schedule the learner for the Antineoplastic Therapy and Immunotherapy Course Exam for On-Demand Course. Upon passing the test, with a score of 80% or greater the learner will receive certificate of completion for the activity.
The course components include: Video Lectures, Course Evaluation and Antineoplastic Therapy and Immunotherapy Course Test.
To enroll, choose Register and scroll to the bottom of the page and choose Enroll.
Target Audience
Licensed healthcare professionals working in Oncology or with Oncology Patients including Registered Nurses, Nurse Practitioners, Physican Assistants, and Pharmacists.
Learning Objectives
After completing the activity, the learner will be able to:
Compare and contrast the mechanism of action between antineoplastic therapy and immunotherapy.
Recall the side effect profiles for the different classes of antineoplastic agents and immunotherapies.
Recall nursing care considerations for patients receiving antineoplastic therapy and immunotherapy.
Compare and contrast the mechanisms of action, side effect profile, complications, and management of side effects for patients receiving novel treatment modalities including Car T-cell therapy, BiTE therapy, and TIL cell therapy.
Describe the role that chemotherapy protectants play in the treatment of cancer.
Recall patient barriers to adherence of oral cancer medications.
Apply principles of antineoplastic therapy drug administration in calculating drug doses to include calculation of body surface area (BSA), absolute neutrophil count (ANC), creatinine clearance (Cr Cl) and carboplatin dosing.
Describe the steps to ensure safe administration of antineoplastic and immunotherapy agents.
Identify assessment priorities to effectively manage patient symptoms, dose-limiting toxicities, and adverse effects of antineoplastic therapy and immunotherapy.
Recognize relevant resources for proper use of personal protective equipment (PPE) and excretion precautions.
Prioritize the appropriate interventions for the management of hypersensitivity reactions.
Describe the appropriate interventions for the management of vesicant extravasation.
Discuss the differences between cancer genetics and cancer genomics.
Identify the role that growth factors play when treating oncology patients.
Recall strategies to prevent medication errors.
.
Additional Information
Speaker | Length | |
Welcome and Course Overview | Lynne OConnor | 20 min |
Principles of Antineoplastic Drug Therapy | Earnie Sanchez | 40 min |
Administration | Markie Rearick | 75 min |
Extravasation | Nancy Birus | 30 min |
Hypersensitivity | Alyssa Owens | 40 min |
Error Prevention | Amy DiMaggio | 40 min |
Build Your Knowledge | Lynne OConnor | 50 min |
Alkylating Agents | Trish Seaman | 50 min |
Chemotherapy Protectants | Lynne OConnor | 35 min |
Genetics vs. Genomics | Melissa Bourdius | 40 min |
Antimetabolites | Tim George | 60 min |
Antitumor Antibodies | Steve Morelli | 60 min |
Cytokines and Vaccines | Tim George | 50 min |
Growth Factors | Emily Mueseler | 30 min |
Organ Toxicities | Linda Pfeiffer | 60 min |
Misc Agents | Tim Brenner | 120 min |
Hormone Therapy: Breast | Courtney Stetor | 30 min |
Hormone Therapy: Prostate | Tom Boyer | 40 min |
Adoptive cellular therapy and BiTE therapy | Shrina Duggal | 60 min |
Monoclonal Antibodies Part 1 | Melissa Bastacky | 80 min |
Monoclonal Antibodies Part 2 | Melissa Bastacky | 55 min |
Tyrosine Kinase Inhibitors Part 1 | Amanda Agnew | 60 min |
Tyrosine Kinase Inhibitors Part 2 | Jason Steele | 65 min |
Oral Adherence | Nancy Birus | 40 min |
Plant Alkaloids | Marissa Lamary | 30 min |
Homework Review | Lynne OConnor | 30 min |
Case Study | Maura Miller | 30 min |
Post Course Instructions | Lynne OConnor | 30 min |
Amanda Agnew, PharmD, BCPS, BCOP
Clinical Oncology Pharmacist
UPMC Hillman Cancer Center
Melissa Bastacky, PharmD, BCOP
Clinical Pharmacy Specialist
UPMC Hillman Cancer Center
Nancy Birus MSN, RN, OCN
Clinical Education Specialist
UPMC Hillman Cancer Center
Melissa K. Bourdius, MS, CGC
Genetics Counselor
Special Genetic Counsel
UPMC Magee-Womens Hospital
Tom G. Boyer, PA-C
Physician Assistant
University of Pittsburgh Physicians
Tim Brenner, PharmD, BCOP
Clinical Pharmacy Specialist
UPMC Hillman Cancer Center
Amy DiMaggio, MSN, RN, OCN
Clinical Education Specialist
UPMC Hillman Cancer Center
Shrina Duggal, PharmD, BCOP
Lead Clinical Oncology Pharmacist
UPMC Hillman Cancer Center
Timothy George, PharmD, BCOP
Clinical Pharmacy Specialist
UPMC Hillman Cancer Center
Marissa Lamary, PA-C
Physician Assistant
UPMC Hillman Cancer Center
UPMC Shadyside
Maura Miller DNP, APRN, FNP-BC, OCN
Clinical Education Specialist
UPMC Hillman Cancer Center
Steve Moretti, PharmD
Oncology Consultant Pharmacist
Investigational Drug Service Pharmacy
UPMC Hillman Cancer Center Shadyside
Emily Mueseler, MPAS, PA-C
Physician Assistant
UPMC Hillman Cancer Center
Lynne O’Connor, MSN, RN, OCN
Clinical Education Specialist
UPMC Hillman Cancer Center
Alyssa Owens, MPAS, PA-C
Physician Assistant
UPMC Hillman Cancer Center
Linda Pfeifer, CRNP, RN
Nurse Practitioner
UPMC Hillman Cancer Center
Markie Rearick, MSN, RN, BMTCN
Clinical Education Specialist
UPMC Shadyside
Ernest M. Sanchez, Pharm.D.
Lead Pharmacist of Oncology Operations, Department of Pharmacy
UPMC Shadyside Hospital
Jason Steele, PharmD, BCOP
Oncology Clinical Pharmacist
UPMC Hillman Cancer Center
Courtney Stetor, MPAS PA-C
Physician Assistant
UPMC Hillman Cancer Center
Disclaimer Statement:
The information presented at this activity represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the UPMC Center for Continuing Education in the Health Sciences, UPMC / University of Pittsburgh Medical Center or Affiliates and University of Pittsburgh School of Medicine. Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Assistant (AAPA)
The University of Pittsburgh has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 22.75 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Nursing (CNE)
The maximum number of hours awarded for this Continuing Nursing Education activity is 22.75 contact hours.
Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.
Available Credit
- 22.75 AAPA Category I CME
- 22.75 ANCCUPMC Provider Unit is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation
- 22.75 Attendance